<DOC>
	<DOCNO>NCT01519661</DOCNO>
	<brief_summary>This study assess long term safety data use tobramycin inhalation powder patient suffer cystic fibrosis chronic pulmonary infection Pseudomonas aeruginosa .</brief_summary>
	<brief_title>Long Term Safety Tobramycin Inhalation Powder Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Confirmed diagnosis Cystic Fibrosis FEV1 screen must 25 75 percent normal predict value age , sex height base Knudson equation Pseudomonas aeruginosa must present sputum / deep cough throat swab culture bronchoalveolar lavage within 6 month prior screen sputum/deepthroat cough swab culture screen History sputum culture deep cough throat swab culture yield Burkholderia cenocepacia complex within 2 year prior screen /or sputum culture yield Burkholderia cenocepacia screen Hemoptysis 60mL time within 30 day prior study drug administration History hear loss chronic tinnitus deem clinically significant Serum creatinine 2mg/dl , BUN 40mg/dl , abnormal urinalysis define 2+ great proteinuria screen Known local systemic hypersensitivity aminoglycosides inhale antibiotic Patients regularly receive 1 class inhale antipseudomonal antibiotic Any use inhale systemic antipseudomonal antibiotic within 28 day prior study drug administration Use loop diuretic within 7 day prior study drug administration Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Tobramycin Inhalation powder</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Lung disease</keyword>
	<keyword>Anti-bacterial agent</keyword>
</DOC>